Business Wire

GN-CORPORATION

12.10.2021 08:37:04 CEST | Business Wire | Press release

Share
COVID-19: Cytokine Storm and Coagulopathy Markers Controlled With Nichi Glucan Variants; The First of Its Kind Report in a Clinical Study

Cytokine storm and coagulopathy, the major life-threatening complications of COVID-19, whose biomarkers Interleukin-6 and D-Dimer were under control with consumption of two variants of Nichi Glucan food supplements from Japan in a pilot study. Immune parameters like ratios of neutrophil to lymphocyte (NLR ), lymphocyte to c-reactive protein (LCR ) and leucocyte to c-reactive protein (LeCR ) were advantageous, along with CD4 and CD8 levels, in those who consumed Nichi Glucans than, those who didn’t, as published in Biomedicine and Pharmacotherapy, a peer reviewed journal (https://www.sciencedirect.com/science/article/pii/S0753332221010271 ).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211011005726/en/

The Covid-19 infection by SARS-COV-2 virus leads to several complications and those have succumbed to the illness developed cytokine storm because of an overreacting immune system, that should be tackled with immunomodulation. According to Dr Raghavan, the first author of the publication, the AFO-202 strain of Black Yeast Aureobasidium Pullulans produced Nichi-Glucan enhances the immune system, while the N-163 strain produced Nichi-Glucan REFIX, efficiently modulates immunity, avoiding any catastrophe. Their combination has yielded this encouraging outcome and our interpretations are based on the present study as well as pre-clinical and clinical studies in healthy volunteers, he added (https://doi.org/10.1101/2021.08.05.21261640 ).

Criteria such as NLR, LCR and LeCR have recently gained significance in assessing Covid-19 severity, which we have documented to be advantageous with Nichi Glucan consumption in healthy people and pre-clinically as well (https://www.researchsquare.com/article/rs-771315/v1 ). Having been proven to handle the immune system in a balanced manner and with potentials of Beta glucans to act through microglia of the brain (Journal of the neurological sciences; https://www.jns-journal.com/article/S0022-510X(21)00248-3/fulltext ), the Nichi glucan variants, with a safety track record of more than two decades may help tackle long Covid-19 also, concludes the study.

In the 1980s, evolution inspired, Prof Noboru Fujii started exploring this poly-extremo tolerant fungus, that was nature gifted . Positioned in the tree of life between animal and plant kingdom, the R&D team believes that the symbiosis of this prebiotic product with gut microbiome may unravel the mechanisms behind its multiple beneficial effects to human health.

GN Corporation, holding the exclusive global distribution rights of the Nichi Glucans, are pursuing elaborate research in bringing out the hidden potentials of several strains of this black yeast fungi produce and plan to undertake larger studies.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NIQ Redefines Packaging Intelligence with Monthly, Harmonized Global Performance Visibility27.3.2026 11:00:00 CET | Press release

NIQ’s new solution brings unprecedented clarity into package types, materials, and true consumption across markets, closing critical industry gaps NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the launch of its Packaging Strategic Planner Global (SPG) Solution, the first harmonized global platform to deliver monthly visibility into packaging performance across materials, formats, and pack configurations. As packaging innovation accelerates, many organizations continue to rely on fragmented or annual data to inform packaging decisions. The Packaging SPG Solution closes this gap by providing real-time data delivered monthly across regions, enabling brands and packaging partners to uncover trends, grow revenue, and strengthen relationships with CPG and retail partners. Key Highlights: New monthly global packaging tracking capability Coverage across 200+ categories Visibility into 30+ package types and 20 package materials 10+ markets at launch, expanding

European DataWarehouse Claims Its First “Fintech Provider of the Year” Award and a Sixth “Data Provider of the Year” Title at GlobalCapital’s 2026 European Securitisation Awards27.3.2026 08:47:00 CET | Press release

European DataWarehouse (EDW) is pleased to announce that it has been named both “Data Provider of the Year” and “Fintech Provider of the Year” at the 2026 GlobalCapital European Securitization Awards in London. The award ceremony recognises outstanding achievements in European structured finance, with winners selected by popular vote from across the industry. As defined by GlobalCapital, the programme celebrates “the very best in the market, as chosen by the market.” This latest recognition marks the sixth time that EDW has received the prestigious Data Provider of the Year award, having previously been honoured in 2019, 2022, 2023, 2024 and 2025, reaffirming its long-standing commitment to transparency, data quality and innovation in European securitisation. Prof. José Manuel González-Páramo, Chairman of EDW, later commented: “ Winning this award for the sixth time highlights the continued trust the European securitisation market places in EDW. Transparency, data quality and reliabili

Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 01:00:00 CET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh

Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting26.3.2026 21:30:00 CET | Press release

Spring is in full swing at the “World’s Most Famous Building.” The Empire State Building (ESB) today announced a vibrant lineup of spring events in NYC, which include special experiences, treat pop-ups, and an iconic tower lighting that captures the joy and color of the beautiful season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326216271/en/ Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting “The Empire State Building Observation Deck has transformed into a celebration of the season and one of the best things to do in NYC this spring,” said Dan Rogoski, observatory general manager. “Whether it’s views beside our butterfly installation, sweet pop-ups, or a chance to spot the Easter Bunny, there is something special for every visitor.” Flutter of Color: The Empire State Building installed a brand-new photo opportunity on the 86th Floor Observati

Venture Global and Edison Announce Calcasieu Pass Arbitration Settlement26.3.2026 21:15:00 CET | Press release

Today, Venture Global and Edison jointly announced the signature of a commercial agreement for the settlement of the pending arbitration between the two companies concerning the Calcasieu Pass project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326559130/en/ Completion of the settlement is expected by the end of Q2 2026, at which point the arbitration will be terminated. The agreement fully resolves the arbitration in its entirety. As part of the settlement, Edison and Venture Global have also agreed to the delivery to Europe of additional cargoes beyond those envisaged under the long-term contract, to support gas supplies primarily to the Italian market. The first delivery is scheduled for May 2026, in Italy, at the Adriatic LNG Terminal. The agreement represents a significant step in strengthening commercial cooperation between the parties and it establishes a foundation for further future deliveries in the context

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye